Takeda, Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Alzheimers Dement. 2023 Mar;19(3):956-966. doi: 10.1002/alz.12697. Epub 2022 Jul 12.
This report details the approach taken to providing a dataset allowing for analyses on the performance of recently developed assays of amyloid beta (Aβ) peptides in plasma and the extent to which they improve the prediction of amyloid positivity.
Alzheimer's Disease Neuroimaging Initiative plasma samples with corresponding amyloid positron emission tomography (PET) data were run on six plasma Aβ assays. Statistical tests were performed to determine whether the plasma Aβ measures significantly improved the area under the receiver operating characteristic curve for predicting amyloid PET status compared to age and apolipoprotein E (APOE) genotype.
The age and APOE genotype model predicted amyloid status with an area under the curve (AUC) of 0.75. Three assays improved AUCs to 0.81, 0.81, and 0.84 (P < .05, uncorrected for multiple comparisons).
Measurement of Aβ in plasma contributes to addressing the amyloid component of the ATN (amyloid/tau/neurodegeneration) framework and could be a first step before or in place of a PET or cerebrospinal fluid screening study.
The Foundation of the National Institutes of Health Biomarkers Consortium evaluated six plasma amyloid beta (Aβ) assays using Alzheimer's Disease Neuroimaging Initiative samples. Three assays improved prediction of amyloid status over age and apolipoprotein E (APOE) genotype. Plasma Aβ42/40 predicted amyloid positron emission tomography status better than Aβ42 or Aβ40 alone.
本报告详细介绍了提供数据集的方法，这些数据集可用于分析最近开发的血浆淀粉样蛋白β（Aβ）肽分析方法的性能，以及它们在多大程度上提高了淀粉样蛋白阳性的预测能力。
使用阿尔茨海默病神经影像学倡议（Alzheimer's Disease Neuroimaging Initiative，ADNI）的血浆样本和相应的淀粉样蛋白正电子发射断层扫描（positron emission tomography，PET）数据，对六种血浆 Aβ 分析方法进行了分析。进行了统计检验，以确定与年龄和载脂蛋白 E（apolipoprotein E，APOE）基因型相比，血浆 Aβ 测量值是否显著提高了预测淀粉样蛋白 PET 状态的受试者工作特征曲线下面积（area under the receiver operating characteristic curve，AUC）。
年龄和 APOE 基因型模型预测淀粉样蛋白状态的 AUC 为 0.75。三种分析方法将 AUC 提高到 0.81、0.81 和 0.84（P <.05，未经多重比较校正）。
血浆 Aβ 的测量有助于解决 ATN（淀粉样蛋白/tau/神经退行性变）框架中的淀粉样蛋白成分，并且可以在 PET 或脑脊液筛选研究之前或替代该研究进行。
美国国立卫生研究院生物标志物联合会（National Institutes of Health Biomarkers Consortium）使用阿尔茨海默病神经影像学倡议（Alzheimer's Disease Neuroimaging Initiative，ADNI）样本评估了六种血浆淀粉样蛋白β（Aβ）分析方法。三种分析方法提高了年龄和载脂蛋白 E（apolipoprotein E，APOE）基因型对淀粉样蛋白状态的预测能力。与 Aβ42 或 Aβ40 单独相比，血浆 Aβ42/40 预测淀粉样蛋白正电子发射断层扫描（positron emission tomography，PET）状态的效果更好。
